Evidence map›Paper›PMID 31500621›Full record

ArticleBMC urology2019

Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience.

Christoph Oehler, Michel Zimmermann, Lukas Adam, Juergen Curschmann, Marcin Sumila, Räto T Strebel, Richard Cathomas, Qiyu Li, Uwe Schneider, Daniel R Zwahlen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christoph OehlerDepartment of Radiation Oncology, Kantonsspital Graubünden, Loëstrasse 170, 7000, Chur, Switzerland. christoph.oehler@ksgr.ch.ORCID http://orcid.org/0000-0003-1649-9187
Michel ZimmermannDepartment of Radiation Oncology, Kantonsspital Graubünden, Loëstrasse 170, 7000, Chur, Switzerland.
Lukas AdamDepartment of Radiation Oncology, Kantonsspital Graubünden, Loëstrasse 170, 7000, Chur, Switzerland.
Juergen CurschmannCenter for Radiation Oncology, Hirslanden Klinik, Zürich, Switzerland.
Marcin SumilaCenter for Radiation Oncology, Hirslanden Klinik, Zürich, Switzerland.
Räto T StrebelDepartment of Urology, Kantonsspital Graubünden, Chur, Switzerland.
Richard CathomasDivision of Medical Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Qiyu LiStatistics Unit, SAKK Coordinating Center, Bern, Switzerland.
Uwe SchneiderCenter for Radiation Oncology, Hirslanden Klinik, Zürich, Switzerland.
Daniel R ZwahlenDepartment of Radiation Oncology, Kantonsspital Graubünden, Loëstrasse 170, 7000, Chur, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients presenting with limited nodal recurrence following radical prostatectomy (RP), stereotactic body radiotherapy (SBRT) results might improve with a better case selection.

methodsSingle-institution retrospective analysis of patients presenting with 1-3 lymph node (LN) recurrences (N1 or M1a) on 18F-Choline PET/CT. Prior therapy included radical prostatectomy (RP) ± salvage radiotherapy (RT), in absence of any systemic therapy. Outcome parameters were biochemical response (BR), time to biochemical recurrence (TBR) and time interval between SBRT and androgen deprivation therapy start (TADT). Time to event endpoints was analysed using Kaplan-Meier method. Potential prognostic factors were examined using univariate proportional hazards regression for TADT and logistic regression for BR. The optimal cut-off point for LN size was calculated using the Contal and O'Quigley method.

results25 patients fulfilling study criteria were treated with SBRT from January 2010 to January 2015 and retrospectively analysed. Median follow up was 18 months and median LN diameter 10.5 mm. SBRT was delivered to a median dose of 36 Gy in three fractions (range: 30-45 Gy). BR was reached in 52% of cases. Median TBR was 11.9 months and significantly longer in patients with larger LN (Hazard ratio [HR] = 0.87, P = 0.03). Using 14 mm as cut off for LN, median TBR was 10.8 months for patients with small LN (18 patients), and 21.2 months for patients with large LN (6 patients) (P unadjusted = 0.009; P adjusted = 0.099). ADT was started in 32% of patients after a median follow-up of 18 months.

conclusionsFor PCa patients with 1-3 LN recurrence after RP (± salvage RT), SBRT might result in a better biochemical control when delivered to larger sized (≥ 14 mm) LN metastases. This study is hypothesis generating and results should be tested in a larger prospective trial.

Indexed as

RadiosurgerySalvage TherapyAgedAged, 80 and overForecastingHumansLymphatic MetastasisMaleMiddle AgedNeoplasm Recurrence, LocalProstatic NeoplasmsRetrospective StudiesTreatment OutcomeBody radiotherapyLymph node metastasesProstate cancerRecurrenceSalvage therapyStereotactic

Identifiers

PMID31500621
PMCPMC6734440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.